China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK PharmaTech (Suzhou) Co., Ltd., an RNA-targeted therapies developer with operations in Boston, US, and Suzhou and Beijing, China. The collaboration aims to develop an angiotensinogen (AGT)-targeted small nucleic acid (siRNA) drug for the treatment of hypertension, with Huadong securing the exclusive option for development, registration, manufacturing, and commercialization rights in Greater China.
Joint Development of SNK-2726 siRNA Drug
Under the terms of the agreement, Huadong Medicine and SynerK PharmaTech will jointly develop SNK-2726, an siRNA drug developed by SynerK and currently being prepared for an Investigational New Drug (IND) filing. Huadong has the exclusive option to exercise an exercise fee in the future to gain the rights for the exclusive development, registration, production, and commercialization of SNK-2726 in the Greater China region.
Financial Arrangements and Milestones
Upon the exercise of its rights by Huadong, SynerK will be entitled to receive subsequent research and development milestones and sales milestones, as well as tiered royalties based on net sales after the commercialization of SNK-2726. This financial structure aligns the interests of both companies and ensures a collaborative approach to bringing this innovative treatment to market.-Fineline Info & Tech
